Is Cellectis S.A. (CLLS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 25.5% / 30% | 72.7% / 30% | 6.4% / 30% | 27.17% / 5% | ✗ NOT HALAL |
| DJIM | 25.5% / 33% | 72.7% / 33% | 6.4% / 33% | 27.17% / 5% | ✗ NOT HALAL |
| MSCI | 23.8% / 33% | 67.9% / 33% | 6.0% / 33% | 27.17% / 5% | ✗ NOT HALAL |
| S&P | 25.5% / 33% | 72.7% / 33% | 6.4% / 33% | 27.17% / 5% | ✗ NOT HALAL |
| FTSE | 23.8% / 33% | 67.9% / 33% | 6.0% / 50% | 27.17% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -142.1% | |
| Net Margin | -84.9% | |
| Return on Equity (ROE) | -65.3% | |
| Return on Assets (ROA) | -5.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $23M |
| Free Cash Flow | $19M |
| Total Debt | $91M |
| Debt-to-Equity | 114.2 |
| Current Ratio | 1.6 |
| Total Assets | $384M |
Price & Trading
| Last Close | $3.19 |
| 50-Day MA | $3.75 |
| 200-Day MA | $3.40 |
| Avg Volume | 50K |
| Beta | 2.8 |
|
52-Week Range
$1.10
| |
About Cellectis S.A. (CLLS)
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cellectis S.A. (CLLS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cellectis S.A. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cellectis S.A.'s debt ratio?
Cellectis S.A.'s debt ratio is 25.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 23.8%.
What are Cellectis S.A.'s key financial metrics?
Cellectis S.A. has a market capitalization of $310M, and revenue of $42M. The company maintains a gross margin of 100.0% and a net margin of -84.9%. Return on equity stands at -65.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.